Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Invesco Ltd.

Invesco Ltd. grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 24.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,006,462 shares of the company's stock after purchasing an additional 979,858 shares during the period. Invesco Ltd. owned approximately 1.30% of Moderna worth $208,169,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Wilmington Savings Fund Society FSB lifted its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after acquiring an additional 587 shares during the period. Compass Planning Associates Inc acquired a new stake in shares of Moderna in the fourth quarter valued at about $37,000. Venturi Wealth Management LLC lifted its stake in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the period. Crowley Wealth Management Inc. purchased a new stake in Moderna during the fourth quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Performance

Shares of NASDAQ MRNA traded down $0.56 during midday trading on Tuesday, hitting $26.24. The company's stock had a trading volume of 7,020,370 shares, compared to its average volume of 7,196,523. The firm's fifty day moving average price is $31.40 and its 200-day moving average price is $40.57. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The firm has a market cap of $10.14 billion, a P/E ratio of -2.83 and a beta of 2.23.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MRNA shares. Leerink Partners reduced their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Bank of America lowered their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. UBS Group cut their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research report on Wednesday, February 19th. Evercore ISI set a $50.00 price target on shares of Moderna in a research report on Friday, February 14th. Finally, Berenberg Bank lifted their price objective on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and an average target price of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.